BusinessFibroGen Announces Publication of Pamrevlumab (FG-3019) Clinical Data in Pancreatic Cancer Showing Safety and Improved Survival Outcomes in Combination with ChemotherapyBy Nasdaq OMXFeb 3, 2017, 4:06 PM UTC
BusinessPamrevlumab Pancreatic Cancer Clinical Data Presented at ASCO 2017 Gastrointestinal Cancers SymposiumBy Nasdaq OMXJan 20, 2017, 10:06 PM UTC
BusinessFibroGen Reports Financial Results for the Third Quarter of 2016 and Provides Corporate UpdateBy Nasdaq OMXNov 8, 2016, 9:03 PM UTC
